KCM
FOLD

Knoll Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Knoll Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-50,000
Closed -$357K – 16
2017
Q1 		$357K Buy
+50,000
New +$316K 0.54% 17

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Knoll Capital Management's FOLD Position: Q2 2017 in Review

Knoll Capital Management sold out of Amicus Therapeutics (FOLD) in Q2 2017, closing a stake of 50,000 shares — an estimated $357K sold.

Knoll Capital Management first reported a position in FOLD in Q1 2017 and held it in 1 quarter. The position peaked at $357K in Q1 2017. 141 funds tracked by Wall St. Rank hold FOLD as of Q2 2017.

  • Knoll Capital Management reported no remaining Amicus Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Knoll Capital Management sold 50,000 Amicus Therapeutics shares in Q2 2017, an estimated $357K.
  • Knoll Capital Management first reported a position in Amicus Therapeutics in Q1 2017 and held it in 1 quarter.
  • Knoll Capital Management's Amicus Therapeutics position peaked at $357K in Q1 2017.
  • 141 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2017.

Based on Knoll Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.